Cargando…
TGFβ: Signaling Blockade for Cancer Immunotherapy
Discovered over four decades ago, transforming growth factor β (TGFβ) is a potent pleiotropic cytokine that has context-dependent effects on most cell types. It acts as a tumor suppressor in some cancers and/or supports tumor progression and metastasis through its effects on the tumor stroma and imm...
Autores principales: | Chen, Szu-Ying, Mamai, Ons, Akhurst, Rosemary J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645596/ https://www.ncbi.nlm.nih.gov/pubmed/36382146 http://dx.doi.org/10.1146/annurev-cancerbio-070620-103554 |
Ejemplares similares
-
Enhanced TGF-β Signaling Contributes to the Insulin-Induced Angiogenic Responses of Endothelial Cells
por: Budi, Erine H., et al.
Publicado: (2019) -
Complexities of TGF-β Targeted Cancer Therapy
por: Connolly, Erin C., et al.
Publicado: (2012) -
Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy
por: Groeneveldt, Christianne, et al.
Publicado: (2023) -
Transforming growth factor-β in breast cancer: too much, too late
por: Barcellos-Hoff, Mary Helen, et al.
Publicado: (2009) -
Targeting TGFβR2‐mutant tumors exposes vulnerabilities to stromal TGFβ blockade in pancreatic cancer
por: Huang, Huocong, et al.
Publicado: (2019)